# Phase 3 Renal Insufficiency, Chronic trials: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 3 for Renal Insufficiency, Chronic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Renal Insufficiency, Chronic trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/renal-insufficiency-chronic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931547 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931547) |
| October 22, 2026 | NCT07890584 | A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | Pathalys Pharma | Phase 3 | Not yet recruiting | Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890584) |
| August 10, 2026 | NCT07753993 | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease | 7,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753993) |
| June 11, 2026 | NCT07642050 | A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy | Biohaven Therapeutics Ltd. | Phase 3 | Not yet recruiting | IgA Nephropathy | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642050) |
| June 4, 2026 | NCT07625774 | Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease | Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Chronic Kidney Disease | 3,690 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625774) |
| June 3, 2026 | NCT07624305 | A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) | AstraZeneca | Phase 3 | Recruiting | Renal Insufficiency, Chronic | 2,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624305) |
| May 19, 2026 | NCT07596329 | Outpatient Hypertonic Saline and Loop Diuretic Combination Therapy in Cardiorenal | University of Monastir | Phase 3 | Not yet recruiting | Heart Failure, Renal Disease, Chronic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596329) |
| March 27, 2026 | NCT07498335 | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN | Novartis Pharmaceuticals | Phase 3 | Recruiting | Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type... | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07498335) |
| February 19, 2026 | NCT07419828 | A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease | Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Recruiting | Chronic Kidney Disease | 5,386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419828) |
| January 28, 2026 | NCT07374042 | Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION) | University Hospital, Clermont-Ferrand | Phase 3 | Recruiting | Kidney Disease, Chronic | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374042) |
| November 21, 2025 | NCT07241390 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney... | Eli Lilly and Company | Phase 3 | Recruiting | Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease | 7,140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241390) |
| August 14, 2025 | NCT07122401 | Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Phase 3 | Recruiting | Secondary Hyperparathyroidism, Chronic Kidney Disease | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07122401) |
| May 31, 2025 | NCT06998862 | Colchicine in Chronic Kidney Disease Patients | Hospital General Universitario Gregorio Marañon | Phase 3 | Recruiting | Chronic Kidney Disease, Cardiovascular Events | 744 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06998862) |
| May 21, 2025 | NCT06982079 | Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease | Ain Shams University | Phase 3 | Recruiting | Chronic Kidney Disease Stage 5, CKD Stage 4 | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06982079) |
| April 18, 2025 | NCT06933472 | A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China | Alebund Pharmaceuticals | Phase 3 | Recruiting | Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06933472) |
| March 5, 2025 | NCT06858319 | Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. | Novartis Pharmaceuticals | Phase 3 | Recruiting | Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06858319) |
| March 5, 2025 | NCT06858280 | Patiromer and Diet/hrQoL in Chronic Dialysis | Mario Negri Institute for Pharmacological Research | Phase 3 | Recruiting | Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4, Dietary Intervention | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06858280) |
| February 11, 2025 | NCT06820567 | Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD | Assiut University | Phase 3 | Not yet recruiting | Chronic Kidney Diseases, Diabetes Type 2 | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06820567) |
| December 19, 2024 | NCT06742723 | A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With... | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease and Hypertension | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06742723) |
| August 29, 2024 | NCT06578533 | Keeping RAASi Treatment With Optimal Potassium Control | Fundación para la Investigación del Hospital Clínico de Valencia | Phase 3 | Recruiting | Chronic Kidney Diseases | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06578533) |
| August 29, 2024 | NCT06578078 | A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | Fundación para la Investigación del Hospital Clínico de Valencia | Phase 3 | Recruiting | Heart Failure, Chronic Kidney Diseases | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06578078) |
| March 29, 2024 | NCT06337838 | Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial | Hamilton Health Sciences Corporation | Phase 3 | Recruiting | Chronic Kidney Diseases, Acute Kidney Injury, Bleeding, Surgery | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06337838) |
| March 26, 2024 | NCT06329622 | Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease | Huashan Hospital | Phase 3 | Recruiting | Chronic Kidney Disease, Sarcopenia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06329622) |
| September 28, 2023 | NCT06058585 | The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect | The George Institute | Phase 3 | Recruiting | Chronic Kidney Diseases | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06058585) |
| February 17, 2023 | NCT05732727 | Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN... | University Hospital, Tours | Phase 3 | Recruiting | Chronic Kidney Disease(CKD), Uncontrolled Hypertension | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05732727) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| [Shandong Suncadia Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shandong-suncadia-medicine-co-ltd) | 2 |
| Fundación para la Investigación del Hospital Clínico de Valencia | 2 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 2 |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 1 |
| [Biohaven Therapeutics Ltd.](https://specstream.ai/data/clinical-trials/company/biohaven-therapeutics-ltd) | 1 |
| Ain Shams University | 1 |
| Hospital General Universitario Gregorio Marañon | 1 |
| [Bayer](https://specstream.ai/data/clinical-trials/company/bayer) | 1 |
| [AMAG Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/amag-pharmaceuticals-inc) | 1 |
| University Hospital, Tours | 1 |
| University of Monastir | 1 |
| Alebund Pharmaceuticals | 1 |
| The George Institute | 1 |
| Huashan Hospital | 1 |
| University of Colorado, Denver | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| Hamilton Health Sciences Corporation | 1 |
| Mario Negri Institute for Pharmacological Research | 1 |
| Pathalys Pharma | 1 |
| Assiut University | 1 |
| Region Stockholm | 1 |
| University Hospital, Clermont-Ferrand | 1 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 1 |

## By country

| Country | Trials |
| --- | --- |
| Spain | 13 |
| United States | 13 |
| China | 12 |
| South Korea | 10 |
| France | 10 |
| India | 9 |
| Taiwan | 9 |
| Argentina | 8 |
| Malaysia | 8 |
| Canada | 8 |
| Germany | 8 |
| Italy | 8 |
| Mexico | 8 |
| Poland | 8 |
| Turkey (Türkiye) | 7 |
| Australia | 7 |
| Brazil | 7 |
| Czechia | 7 |
| Hungary | 7 |
| Japan | 7 |
| United Kingdom | 7 |
| Greece | 6 |
| Ukraine | 5 |
| Belgium | 5 |
| Israel | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Truck and industrial vehicle companies in the United States](https://specstream.ai/data/businesses/truck-and-industrial-vehicle-companies/united-states)
- [Powder coating companies in the United States](https://specstream.ai/data/businesses/powder-coating-companies/united-states)
- [Kitchen remodelers in the United States](https://specstream.ai/data/businesses/kitchen-remodelers/united-states)
- [Environmental testing companies in the United States](https://specstream.ai/data/businesses/environmental-testing-companies/united-states)
- [British restaurants in the United States](https://specstream.ai/data/businesses/british-restaurants/united-states)
- [Vietnamese restaurants in the United States](https://specstream.ai/data/businesses/vietnamese-restaurants/united-states)
